Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
Open Access
- 25 March 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (3) , e0120451
Abstract
The identification of highly potent broadly neutralizing antibodies (bnAbs) against HIV-1, and success in preventing SHIV infection following their passive administration, have increased the likelihood that immunotherapeutic strategies can be adopted to prevent and treat HIV-1 infection. However, while broad and potent neutralizing activity is an essential prerequisite, in vivo properties such as good circulatory stability and non-immunogenicity are equally critical for developing a human treatment. In the present study, glycoforms of the bnAbs 10-1074, NIH45-46G54W, 10E8, PGT121, PGT128, PGT145, PGT135, PG9, PG16, VRC01 and b12 were produced by Agrobacterium-mediated transient transfection of Nicotiana benthamiana and assessed following administration in rhesus macaques. The results indicate that (i) N-glycans within the VL domain impair plasma stability of plant-derived bnAbs and (ii) while PGT121 and b12 exhibit no immunogenicity in rhesus macaques after multiple injections, VRC01, 10-1074 and NIH45-46G54W elicit high titer anti-idiotypic antibodies following a second injection. These anti-idiotypic antibodies specifically bind the administered bnAb or a close family member, and inhibit the bnAb in neutralization assays. These findings suggest that specific mutations in certain bnAbs contribute to their immunogenicity and call attention to the prospect that these mutated bnAbs will be immunogenic in humans, potentially compromising their value for prophylaxis and therapy of HIV-1.Keywords
This publication has 35 references indexed in Scilit:
- Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodiesProceedings of the National Academy of Sciences, 2012
- Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivoProceedings of the National Academy of Sciences, 2012
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escapeNature Medicine, 2012
- Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedJournal of Experimental Medicine, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Science, 2010
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogensBiochemical and Biophysical Research Communications, 2009
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Cost-effective production of a vaginal protein microbicide to prevent HIV transmissionProceedings of the National Academy of Sciences, 2008